-
Professor Fu Rong: Innovative drugs drive the development of rare disease diagnosis and treatment, and the dilemma of PNH treatment in China is expected to be broken
Time of Update: 2023-01-06
In order to help promote the construction of "Healthy China" and promote the development of rare disease diagnosis and treatment in China, the 2022 China Rare Disease Conference was successfully held
-
Key points for the diagnosis and treatment of gastric mucosa-associated lymphoid tissue lymphoma: 3 minutes speed reading
Time of Update: 2023-01-06
Chinese Journal of Digestion, 2022, 42(5): 289-303The Sixth National Consensus Report on the Treatment of Helicobacter Pylori InfectionFor Hp-positive local stage (Lugano stage I/II) gastric MALT lymphoma, 60%~80% of patients can achieve remission after eradication of Hp. Hp eradication therapy is ineffective for most gastric MALT lymphomas with t(11,18) translocation, which require chemotherapy and/or radiation therapy.
-
Key points for the diagnosis and treatment of gastric mucosa-associated lymphoid tissue lymphoma: 3 minutes speed reading
Time of Update: 2023-01-06
Chinese Journal of Digestion, 2022, 42(5): 289-303The Sixth National Consensus Report on the Treatment of Helicobacter Pylori InfectionFor Hp-positive local stage (Lugano stage I/II) gastric MALT lymphoma, 60%~80% of patients can achieve remission after eradication of Hp. Hp eradication therapy is ineffective for most gastric MALT lymphomas with t(11,18) translocation, which require chemotherapy and/or radiation therapy.
-
【Lymphoma diagnosis and treatment talent construction project】Appeared at the Takeda booth at CIIE to help achieve the goal of "2030 Healthy China"
Time of Update: 2023-01-06
In line with the call of the times, the lymphoma diagnosis and treatment talent construction project sponsored by the Chinese Health Science and Technology Promotion Association has been successfully launched with the cooperation of all parties, which is committed to cultivating lymphoma diagnosis and treatment talents, establishing lymphoma demonstration centers (COE) and lymphoma diagnosis and treatment pathways, helping clinicians improve the level of diagnosis and treatment, improve the cure rate of lymphoma in China, and benefit more Chinese lymphoma patients.
-
Roche's "Blood Stars" shines in the Bo, gathering all parties to benefit Chinese blood disease patients
Time of Update: 2023-01-06
Professor Wu Depei, Chairman of the Hematology Society Branch of the Chinese Medical Association, pointed out: "Nowadays, the development of blood disease treatment is changing with each passing day, and innovative drugs are constantly emerging; The world's first CD79b-targeting antibody drug conjugate (ADC), vepotuzumab, which will be launched in China, is the biggest breakthrough in the field of lymphoma in the past 20 years and is expected to revolutionize the standard of clinical treatment.
-
Roche's "Blood Stars" shines in the Bo, gathering all parties to benefit Chinese blood disease patients
Time of Update: 2023-01-06
Professor Wu Depei, Chairman of the Hematology Society Branch of the Chinese Medical Association, pointed out: "Nowadays, the development of blood disease treatment is changing with each passing day, and innovative drugs are constantly emerging; The world's first CD79b-targeting antibody drug conjugate (ADC), vepotuzumab, which will be launched in China, is the biggest breakthrough in the field of lymphoma in the past 20 years and is expected to revolutionize the standard of clinical treatment.
-
【2022 ASH Field Frontier】Treatment status and stratified prognosis of multiple myeloma
Time of Update: 2023-01-06
Poster #4518The Independent Adverse Prognostic Significance of 1q21 Gain/Amplification in Newly Diagnosed Multiple Myeloma PatientsKey author: Hongying YouKey information: Clinically significant end-stage organ damage and high tumor burden in 1q21+ patients are independent high-risk cytogenetic factors for poor prognosis in patients with NDMM, where 4 or more copy numbers and major clone locations are significantly associated with prognosis.
-
【2022 ASH Field Frontier】Treatment status and stratified prognosis of multiple myeloma
Time of Update: 2023-01-06
Poster #4518The Independent Adverse Prognostic Significance of 1q21 Gain/Amplification in Newly Diagnosed Multiple Myeloma PatientsKey author: Hongying YouKey information: Clinically significant end-stage organ damage and high tumor burden in 1q21+ patients are independent high-risk cytogenetic factors for poor prognosis in patients with NDMM, where 4 or more copy numbers and major clone locations are significantly associated with prognosis.
-
【ASH Express】Reproduce eye-catching data-a quick overview of the blockbuster study of the classic BTK inhibitor ibrutinib
Time of Update: 2023-01-06
The 2022 American Society of Hematology (ASH) Annual Meeting will be held in New Orleans from December 10 to 13 Eastern Time in the form of online + offline, the abstract will be announced at 22:00 Be
-
【ASH Express】Reproduce eye-catching data-a quick overview of the blockbuster study of the classic BTK inhibitor ibrutinib
Time of Update: 2023-01-06
The 2022 American Society of Hematology (ASH) Annual Meeting will be held in New Orleans from December 10 to 13 Eastern Time in the form of online + offline, the abstract will be announced at 22:00 Be
-
Professor Cai Qingqing: New drugs continue to emerge, where is the treatment of relapsed and refractory diffuse large B-cell lymphoma? The 7th International Summit Forum on Anti-Leukemia and Lymphoma
Time of Update: 2023-01-06
CAR-TCAR-T is an effective option for patients with R/R DLLBL who have failed R-CHOP, are not suitable for transplantation, or have failed HDC-ASCT 。 Current CD19-targeting CAR-T cell products for DLBCL include Axicabtagene ciloleucel (Axi-cel, ZUMA-1 study), Tisagenlecleucel (Tisa-cel, JULIET study), and Lisocabtagene maraleucel (Liso-cel, TRANSCEND study), at R/R Higher treatment was shown in all third-line and above treatments for DLBCL: ORR of 52-83% and CR rate of 40% to 58%.
-
Professor Cai Qingqing: New drugs continue to emerge, where is the treatment of relapsed and refractory diffuse large B-cell lymphoma? The 7th International Summit Forum on Anti-Leukemia and Lymphoma
Time of Update: 2023-01-06
CAR-TCAR-T is an effective option for patients with R/R DLLBL who have failed R-CHOP, are not suitable for transplantation, or have failed HDC-ASCT 。 Current CD19-targeting CAR-T cell products for DLBCL include Axicabtagene ciloleucel (Axi-cel, ZUMA-1 study), Tisagenlecleucel (Tisa-cel, JULIET study), and Lisocabtagene maraleucel (Liso-cel, TRANSCEND study), at R/R Higher treatment was shown in all third-line and above treatments for DLBCL: ORR of 52-83% and CR rate of 40% to 58%.
-
Efficacy of Midostaurin in combination with intensive chemotherapy in young and elderly patients with AML with FLT3-ITD mutations
Time of Update: 2023-01-06
In a randomized Phase 3 pivotal CALGB 10603 (RATIFY) trial comparing placebo, patients aged 18 to 59 years with newly diagnosed AML with FLT3 mutation experienced significant improvements in overall survival (OS) and event-free survival (EFS) after receiving midostaurin plus intensive chemotherapy sequential 1-year midostaurin maintenance therapy.
-
Efficacy of Midostaurin in combination with intensive chemotherapy in young and elderly patients with AML with FLT3-ITD mutations
Time of Update: 2023-01-06
In a randomized Phase 3 pivotal CALGB 10603 (RATIFY) trial comparing placebo, patients aged 18 to 59 years with newly diagnosed AML with FLT3 mutation experienced significant improvements in overall survival (OS) and event-free survival (EFS) after receiving midostaurin plus intensive chemotherapy sequential 1-year midostaurin maintenance therapy.
-
Professor Liu Peng from HEMA perspective: RWS in China has identified the benefits of anti-CD20 monoclonal antibody maintenance therapy, providing new evidence for the optimization of FL treatment
Time of Update: 2023-01-06
1Yimaitong: It is understood that your Chinese Academy of Medical Sciences Cancer Hospital Internal Medicine-Lymphoma Treatment Team conducted a real-world study (RWS) with more than 5 years of follow-up for the first time in the era of rituximab in the era of advanced FL in China, and explored the impact of anti-CD20 monoclonal antibody maintenance therapy on patients' treatment outcomes.
-
Professor Qiu Lin: Dynamic monitoring of mutant genes, NGS to help AML personalized precision treatment| the 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2023-01-06
Next-generation sequencing (NGS) plays an important role in the prognosis analysis, efficacy evaluation, recurrence prediction and detection of minimal residual disease (MRD) in acute myeloid leukemia
-
Professor Ying Zhitao: The road ahead is also bright, improve the efficacy of CAR-T, solve the dilemma of CAR-T cell therapy, and the 7th International Summit Forum on Anti-leukemia and Lymphoma is on the road
Time of Update: 2023-01-06
On the occasion of the "7th Anti-Leukemia and Lymphoma International Summit Forum and CSCO Leukemia & Lymphoma Expert Committee Tour - Harbin Station", Yimaitong is honored to invite Professor Ying Zhitao of Peking University Cancer Hospital to be interviewed to introduce the current status of CAR-T cell therapy in lymphoma treatment, and talk about the achievements and future exploration directions of the lymphoma department of Peking University Cancer Hospital (Beiwei).
-
Research Express! Iberdomide in combination with dexamethasone in the treatment of advanced R/R MM is a new progress
Time of Update: 2023-01-06
Multiple myeloma (MM) is characterized by the persistence of minimal residual disease during combination therapy by patients, leading to multiple cycles of remission and recurrence. Each subsequent li
-
Professor Georg Lenz: Exploring the revolution in DLBCL first-line treatment
Time of Update: 2023-01-06
Question 2: Before Pola reimbursement, what do you think is the most suitable treatment population for untreated DLBCL patients?Professor Georg LenzFrom subgroup analysis data, Pola-R-CHP regimens showed more significant benefit in patients with high-risk factors such as IPI score 3 to 5, age > 60 years, double expression, and ABC subtype, and may be biased towards these patients before reimbursement.
-
The original intention is like a torch, hard work is like sail, leukemia and lymphoma special session 1 focuses on the frontier The Harbin branch of the 2022 CSCO Academic Annual Conference
Time of Update: 2023-01-06
Click to read the original article to see more conference videosProfessor Zhang Huilai of Tianjin Medical University Cancer Hospital gave a report entitled "The New Era of Lymphoma Immunotherapy: Breakthroughs and Challenges in Immune Checkpoint Research" from multiple dimensions such as immune dysregulation mechanism and immunotherapy methods.
